-
Don Davis bill would ban federal candidates from betting on their own races
The proposal would cover candidates’ families and campaigns, following Kalshi’s sanction of Davis’s Republican opponent.
-
WBUR examines election prediction markets’ rise and insider-risk concerns
Here & Now host Scott Tong spoke with Anti-Corruption Data Collective co-director Michael Hornsby as political wagers surged
-
Kalshi executive calls election markets positive for democracy amid Michigan fight
Luana Lopes Lara says market prices inform voters, while Michigan and election officials raise gambling, manipulation and insider-trading concerns.
-
Opinion column invokes George Santos ban in warning on prediction markets
The Florida State University commentary argues that personal knowledge, aggressive marketing and concentrated gains expose risks beneath the industry’s financial-exchange claims.
-
House Oversight broadens prediction-market insider-trading inquiry to three platforms
Hyperliquid, Crypto.com and PredictIt’s owner face requests on identity checks, location controls and suspicious trading
-
CFTC opened three Polymarket probes
FOIA records point to private investigations into Biden pardon markets, Iran contracts and Google-themed trades.
-
Kalshi suspends North Carolina candidate over bets on her own race
The Republican nominee said she made a “dumb mistake” after the prediction-market exchange found she bought contracts tied to her campaign and imposed a three-year ban.
-
Kalshi bans George Santos for life over State of Union betting
The prediction market said the former congressman wagered against his own attendance at President Donald Trump’s speech and then tried to move the market with public comments.
-
San Diego County bars officials from prediction-market insider trading
Supervisors also moved to lengthen the county’s lobbying ban and update disclosure rules for Kalshi and Polymarket.
-
Kalshi and AppliedXL launch biopharma prediction markets with strict guardrails
The pilot will let traders price clinical-trial outcomes and FDA decisions, while limiting access to late-stage studies and requiring employment checks.